Clinical Report: Advantages of Using Minimal Ethanol Volume in Sclerotherapy
Overview
This study evaluates the effectiveness of transvaginal ethanol sclerotherapy for endometriomas, emphasizing the benefits of using minimal ethanol volume and retention. Findings indicate that this approach significantly reduces recurrence rates and minimizes the impact on ovarian reserve, as measured by AMH levels.
Background
Ovarian endometriomas affect a significant proportion of women with infertility, presenting challenges in treatment due to their complex nature. Traditional surgical methods, while effective, often compromise ovarian reserve, necessitating the exploration of less invasive alternatives. Ethanol sclerotherapy has emerged as a promising option, particularly for preserving fertility and minimizing damage to ovarian tissue.
Data Highlights
Year
Cases
AMH Follow-up
2015-2022
421
90
Key Findings
Transvaginal sclerotherapy using 95% ethanol was performed on 421 cases.
Retention of ethanol without removal showed lower recurrence rates compared to traditional methods.
Minimal ethanol volume was associated with reduced impact on AMH levels.
Patients had endometriomas ranging from 2.5 to 10.6 cm.
Effective aspiration of viscous cystic content is crucial for successful outcomes.
Clinical Implications
Clinicians should consider transvaginal ethanol sclerotherapy as a viable option for treating ovarian endometriomas, particularly in patients wishing to preserve fertility. The technique's focus on minimal ethanol volume and retention can lead to better outcomes with fewer complications.
Conclusion
The study supports the use of minimal ethanol volume and retention in transvaginal sclerotherapy as an effective strategy for managing endometriomas, highlighting its potential to reduce recurrence and protect ovarian function.
